Gainers

• Cyclerion Therapeutics (NASDAQ:CYCN) shares rose 307.1% to $6.31 during Wednesday's regular session. The market value of their outstanding shares is at $5.8 million.
• Axe Compute (NASDAQ:AGPU) shares increased by 94.44% to $3.15. The market value of their outstanding shares is at $5.4 million. As per the press release, Q4 earnings came out yesterday.
• Regencell Bioscience (NASDAQ:RGC) stock increased by 39.99% to $35.6. The market value of their outstanding shares is at $12.5 billion.
• Cognition Therapeutics (NASDAQ:CGTX) stock rose 26.26% to $0.96. The company's market cap stands at $67.8 million. As per the press release, Q4 earnings came out 4 days ago.
• Jaguar Health (NASDAQ:JAGX) shares rose 22.67% to $0.45. The company's market cap stands at $4.6 million.
• Alector (NASDAQ:ALEC) shares moved upwards by 20.0% to $2.58. The company's market cap stands at $234.6 million.

Losers

• ORIC Pharmaceuticals (NASDAQ:ORIC) stock fell 27.3% to $9.21 during Wednesday's regular session. The market value of their outstanding shares is at $1.4 billion.
• Bristol-Myers Squibb Company Celegne Contingent Value Rights (NYSE:CELGR) stock fell 26.39% to $0.09.
• IO Biotech (NASDAQ:IOBT) shares fell 25.9% to $0.04. The company's market cap stands at $4.2 million.
• BioAtla (NASDAQ:BCAB) shares fell 22.24% to $0.13. The market value of their outstanding shares is at $13.3 million. As per the news, the Q4 earnings report came out yesterday.
• HCW Biologics (NASDAQ:HCWB) shares declined by 17.87% to $0.3. The market value of their outstanding shares is at $1.2 million. As per the news, the Q4 earnings report came out yesterday.
• ENvue Medical (NASDAQ:FEED) shares decreased by 16.39% to $1.99. The market value of their outstanding shares is at $2.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.